Sicherheit unter Biologika – Ergebnisse aus dem deutschen Biologika-Register RABBIT

Schlüsselwörter

Biologika - rheumatoide Arthritis - Arzneimittelsicherheit - Infektionen - Malignome - Mortalität

Keywords

biologics - rheumatoid arthritis - drug safety - infections - malignancies - mortality

• Literatur

• 1 Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among swedish ra-patients treated with tnf-antagonists. Ann Rheum Dis 2007; 66: 1339-1344
• 2 Avina-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697
• 3 Dixon WG, Symmons DP, Lunt M et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-2904
• 4 Dixon WG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62: 755-763
• 5 Dreyer L, Mellemkjaer L, Andersen AR et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry. Ann Rheum Dis 2012; 72: 79-82
• 6 John H, Kitas G, Toms T et al. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 71-82
• 7 Listing J, Kekow J, Manger B et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 2013; Nov 29 [Epub ahead of print]
• 8 Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412
• 9 Listing J, Strangfeld A, Kekow J et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008; 58: 667-677
• 10 Lunt M, Watson KD, Dixon WG et al. No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010; 62: 3145-53
• 11 Strangfeld A, Hierse F, Rau R et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12: R5
• 12 Strangfeld A, Richter A, Meissner Y et al. High risk of developing fatal infections in RA patients with congestive heart failure. Ann Rheum Dis 2014; 73 (Suppl. 02) 124
• 13 Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-732
• 14 Meissner Y, Kühl-Habich D, Kekow J et al. Acute myocardial infarction is driven by chronic inflammation, irrespective of the kind of treatment – Data of the German biologics register RABBIT. Ann Rheum Diss 2013; 72 (Suppl. 03) 744
• 15 Mercer LK, Green AC, Galloway JB et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012; 71: 869-874
• 16 Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 871-883
• 17 Raaschou P, Simard JF, Holmqvist M et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013; 346: f1939
• 18 Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
• 19 Zink A, Manger B, Kaufmann J et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2013;